Naproxen topical - CeNeS

Drug Profile

Naproxen topical - CeNeS

Alternative Names: RS 3540 topical - CeNeS; RS-3540

Latest Information Update: 27 Oct 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Oct 2004 Discontinued - Clinical-Phase-Unknown for Inflammation in United Kingdom (Topical)
  • 16 Dec 1999 Core Group has merged with CeNeS Limited to form CeNeS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top